Gastric pH effects on weak bases and amphetamine formulations
An alkaline gastric environment increases the fraction of amphetamine (a weak base) in the un-ionized form, which generally favors membrane diffusion across the GI epithelium. [1] For amphetamine products, clinically important effects of gastric alkalinization depend more on formulation-dependent release and site of absorption than on chemical degradation in gastric fluid. [1]
Adderall (mixed amphetamine salts) chemical stability in alkaline gastric fluid
Mixed amphetamine salts do not rely on gastric acid–labile chemical bonds for conversion to an active drug. [2] As a weak base, amphetamine exists in a pH-dependent ionization state, so alkalinization primarily changes ionization and partitioning rather than causing chemical breakdown. [1]
Adderall XR (extended-release mixed amphetamine salts) absorption changes with alkalinization
ADDERALL XR contains pH- and formulation-controlled extended-release beads, so increased gastric pH can change the timing and location of drug release. [3] The U.S. prescribing information for ADDERALL XR states that co-administration with GI alkalinizing agents such as antacids should be avoided because GI alkalinizing agents can increase amphetamine absorption. [3] A shortened time-to-peak exposure has been reported when a proton pump inhibitor was co-administered with extended-release mixed amphetamine salts, consistent with earlier or altered release/absorption kinetics. [4]
Vyvanse (lisdexamfetamine) chemical stability in alkaline gastric fluid
Lisdexamfetamine dimesylate is a prodrug that is converted to d-amphetamine after absorption by enzymatic hydrolysis. [5] That enzymatic hydrolysis is not subject to variations in absorption related to gastric pH, supporting chemical and performance stability across gastric pH changes. [5] In human investigations, lisdexamfetamine absorption and conversion to d-amphetamine is described as not varying with gastric pH. [6]
Vyvanse absorption changes with alkalinization
Lisdexamfetamine is characterized as not affected by variations in absorption related to changes in gastric pH or GI transit time. [5] Therefore, gastric alkalinization is not expected to meaningfully change Vyvanse systemic exposure through altered prodrug conversion within the stomach. [5]
Comparison of formulation-dependent vs prodrug-dependent mechanisms
Adderall XR shows clinically relevant sensitivity to gastric pH–modifying agents because the extended-release mechanism can be affected by gastric acidity. [3] Vyvanse shows reduced sensitivity to gastric pH because the drug conversion process depends predominantly on enzymatic hydrolysis after absorption rather than gastric conditions. [5]
Practical clinical implications of alkalinized gastric environment
Co-administration of ADDERALL XR with GI alkalinizing agents (including antacids and acid-suppressing therapy) is recommended to be avoided due to increased absorption risk. [3] When gastric pH is modified, monitoring for changes in clinical effect is emphasized for extended-release mixed amphetamine salt formulations in FDA review materials. [7] Gastric pH modification is not expected to substantially affect Vyvanse absorption via altered gastric conversion, so clinically meaningful exposure changes are less likely through this mechanism. [5]
Key evidence supporting these effects
General pharmacology principles support pH-dependent ionization effects for weak bases, which can influence absorption behavior. [1] Human pharmacokinetic evidence for lisdexamfetamine describes conversion after absorption with lack of gastric-pH–dependent absorption variability. [6] A published adult pharmacokinetic study evaluated omeprazole with lisdexamfetamine and extended-release mixed amphetamine salts, providing direct comparison of gastric pH–modulated kinetics across both drug types. [4]